All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy

European Heart Journal

Volumn 31, Issue 18, 2010, Pages 2271-2279

  Okin, Peter M ^a   Kjeldsen, Sverre E ^b,c   Julius, Stevo ^c   Hille, Darcy A ^d   Dahlöf, Björn ^e   Edelman, Jonathan M ^d   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Electrocardiography; Heart rate; Hypertension; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; IDIOPATHIC DISEASE; LUNG PARENCHYMA; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; TREATMENT RESPONSE; UPREGULATION;

AGED; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIAS, CARDIAC; ATENOLOL; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KAPLAN-MEIER ESTIMATE; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77956912430     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq225     Document Type: Article

References (29)

1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif J-C, Tavazzi L, Tendera M, for the Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-830.
2. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 2009;52:46-60.
3. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987;113:1489-1494.
4. Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 2008;29:2772-2781.
5. Jouven X, Empana JP, Escolano S, Byyck JF, Tafflet M, Desnos M, Ducimetière P. Relation of heart rate at rest and long-term (.20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009;103:279-283.
6. Kolloch R, Legler UF, Champion A, Cooper-DeHoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil- SR/trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-1334.
7. Gillman M, Kannel WB, Belanger A, DAgostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 1993;125:1148-1154.
8. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, OBrien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162: 2313-2321.
9. Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NRC, on behalf of the ASCOT investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Ango-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009;54:1154-1161.
10. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol 2008;1:337-343.
11. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JMC, Dominiczak AF, McInnes GT, Padmanabhan S. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010;55:567-574.
12. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events. JAMA 2004;292:2343-2349. (Pubitemid 39491918)
13. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S,Wedel H, for the LIFE Study Group. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997;10:705-713.
14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
15. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-423.
16. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-186.
17. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES 1 epidemiologic follow-up study. Am Heart J 1991;121:172-177.
18. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimate. Am Stat 2005;59:301-307.
19. Okin PM. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients. J Electrocardiol 2009;42:584-588.
20. King DE, Everett CJ, Mainous AG III, Liszka HA. Long-term prognostic value of resting heart rate in subjects with prehypertension. Am J Hypertens 2006;19: 796-800.
21. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990;81:850-859.
22. Perski A, Harnstein K, Lindvall K, Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young post-infarction patients. Am Heart J 1988; 116:1369-1373.
23. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104: 1477-1482.
24. Gordon D, Guyton J, Karnovsky N. Intimal alterations in rat aorta induced by stressful stimuli. Lab Invest 1981;45:14-27.
25. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008;126:302-312.
26. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984;226:180-182.
27. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:2377-2387.
28. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004;18:367-373.
29. Fox K, Ford I, Steg G, Tendera M, Ferrari R, on behalf of the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.